Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies.
Vancomycin-resistant enterococci (VRE) are a leading cause of nosocomial infections due to the limited number of effective therapeutic options. In an effort to repurpose FDA-approved drugs against antibiotic-resistant bacteria, we identified auranofin as a potent drug against VRE. The present study determined that auranofin's antibacterial activity was not affected when evaluated against a higher inoculum size of VRE (∼107 CFU/mL), and auranofin successfully reduced the burden of stationary phase VRE cells via a time-kill assay. In addition, auranofin reduced VRE production of key virulence factors including proteases, lipase and hemagglutinin. The promising features of auranofin prompted us to evaluate its in vivo efficacy in a lethal mouse model of VRE septicemia. All mice receiving auranofin at 0.125 mg/kg orally, 0.125 mg/kg subcutaneously (S.C.), or 0.0625 mg/kg (S.C.) survived the lethal VRE challenge. Additionally, auranofin was superior to linezolid, the current drug of choice, in reducing VRE burden in the liver, kidneys and spleen of mice. Remarkably, auranofin successfully reduced VRE below the limit of detection in murine internal organs after only four days of oral or subcutaneous treatment. These results indicate that auranofin warrants further investigation as a new treatment for systemic VRE infections.